Pediatric rheumatic disease: Vaccination in pediatric rheumatic disease - Risks and benefits

Nature Reviews Rheumatology

Volumn 8, Issue 4, 2012, Pages 188-190

  Janow, Ginger ^a   Ilowite, Norman T ^a  

^a CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLUENZA VACCINE; LIVE VACCINE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; WART VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; B LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; OUTCOME ASSESSMENT; PEDIATRIC RHEUMATIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEROCONVERSION; SHORT SURVEY; TETANUS PROPHYLAXIS; VACCINATION;

ANTIRHEUMATIC AGENTS; CHILD; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; RHEUMATIC DISEASES; RISK FACTORS; VACCINES;

EID: 84859442396     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.13     Document Type: Short Survey

References (10)

1. Tynjala, P. et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 70, 1605-1612 (2011).
2. Ilowite, N. T. et al. Impaired in vivo and in vitro antibody responses to bacteriophage phi X 174 in juvenile rheumatoid arthritis. J. Rheumatol. 14, 957-963 (1987).
3. Heijstek, M. W. et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann. Rheum. Dis. 70, 1704-1712 (2011).
4. Aikawa, N. E. et al. Corticosteroid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J. Rheumatol. 39, 167-173 (2012).
5. Dell'era, L. et al. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine 30, 936-940 (2012).
6. Long, C. B. et al. Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk children. J. Pediatr. 160, 74-81 (2012).
7. Rehnberg, M. et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res. Ther. 12, R111 (2010).
8. Perricone, C., Agmon-Levin, N., Valesini, G. & Shoenfeld, Y. Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego. Joint Bone Spine 79, 1-3 (2012).
9. Shoenfeld, Y. & Agmon-Levin, N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 36, 4-8 (2011).
10. Balofsky, A., Agmon-Levin, N. & Shoenfeld, Y. The new H1N1 and HPV vaccines and old fears. Curr. Opin. Rheumatol. 22, 431-436 (2010).